777 replies to this topic

[caliban]

http://www.biotimeinc.com/

[ImmInst]

BioTime, Inc. and XenneX Form LifeMap Sciences, Inc. to Create Roadmap for Regenerative Medicine
Reuters Key Development - 2 hours ago

View the full article

[ImmInst]

BioTime Presents Data at FABS 2011 on the Restoration of Cell Lifespan Using iPS Cell Technology
Business Wire - 47 minutes ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX) and its subsidiary ReCyte Therapeutics, Inc. announced that today, BioTime CEO Dr. Michael West will present at the French-American ...

View the full article

[ImmInst]

BioTime Inc (BTX) Posts Large Volume Increase, Hits $7.10
American Banking News - 18 minutes ago

Shares of BioTime Inc (BTX) saw unusually high trading volume on Tuesday. Approximately 164,902 shares changed hands during mid-day trading, an increase of 14.37% from the previous session. The ...

View the full article

[ImmInst]

BioTime Inc (BTX) Trades Up 5.11%, Hits $7.61
American Banking News - 7 hours ago

Shares of BioTime Inc (BTX) saw major gains on Tuesday. The stock traded up $0.37 or 5.11% for the day and last traded at $7.61. Approximately 376,436 shares changed hands during mid-day trading ...

View the full article

[ImmInst]

Biotechs launch stem cell research joint venture
Lexology - 2 hours ago

By Patrick Henderson, Madeleine McDonough and Thomas T. Moga California-based BioTime Inc. and XenneX Inc. have announced a joint venture to “develop and commercialize a database of the thousands ...

View the full article

[ImmInst]

Bearish Two Hundred Day Moving Average Cross - BTX
MarketNewsVideo.com - 2 hours ago

By Market News Video Staff, Wednesday, April 27, 11:41 AM ET In trading on Wednesday, shares of BioTime, Inc. (AMEX:BTX) crossed below their 200 day moving average of $6.77, changing hands as low ...

View the full article

[ImmInst]

Biotechs launch stem cell research joint venture
Lexology - 9 hours ago

By Patrick Henderson, Madeleine McDonough and Thomas T. Moga California-based BioTime Inc. and XenneX Inc. have announced a joint venture to “develop and commercialize a database of the thousands ...

View the full article

[ImmInst]

BioTime Initiates Clinical Development Program for HyStem®-Rx as a Cell Delivery Device for Reconstructive Surgery and Other Cell-Based Therapies
Business Wire - 30 minutes ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX) announced today that it has elected to seek regulatory approval of HyStem ® -Rx as an implantable cell delivery vehicle that can be ...

BioTime Initiates Clinical Development Program For HyStem®-Rx As A Cell Delivery Device For Reconstructive Surgery And Other Cell-Based Therapies - TheStreet.com

View the full article

[ImmInst]

BioTime Announces First Quarter 2011 Financial Results And Corporate Developments
TheStreet.com - 1 hour ago

By Business Wire 05/05/11 - 04:39 PM EDT BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine and blood ...

View the full article

[ImmInst]

BioTime Announces Issuance Of U.S. Glycosan Hydrogel Patent
TheStreet.com - 50 minutes ago

By Business Wire 05/10/11 - 09:00 AM EDT BioTime, Inc. (NYSE Amex:BTX) announced today the issuance of United States patent number 7,928,069 covering certain aspects of the composition of Glycosan ...

View the full article

[caliban]

Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) is the world’s leading developer of innovative biological products for the broad field of regenerative medicine.

Mesoblast’s commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.

The company’s lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.

Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.

[ImmInst]

Investor Stem Cell Declares 2011 Stem Cell Leaders
Online PR News - 1 hour ago

This year's principal leaders in the sector are as follows: Geron Corporation (NASDAQ;GERN), Advanced Cell Technology (OTC:ACTC), International Stem Cell Corp. (OTC:ISCO), Pluristem Therapeutics ...

View the full article

[ImmInst]

Mesoblast Limited (ASX:MSB) Key Patents Granted In United States Strengthen Commercial Rights And Broaden Clinical Indications
Asia Business News - 24 minutes ago

Melbourne, May 24, 2011 (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the company's product development strategy has ...

View the full article

[ImmInst]

Athersys (Nasdaq: ATHX) Reports Positive Interim Data from Ongoing Phase 1 Study
BiotechStockTrader.com - 1 hour ago

By Justin Kuepper on Wednesday, May 25th, 2011 Athersys Inc. (Nasdaq: ATHX), a biopharmaceutical company focused on developing an innovative stem cell platform, similar to companies like Mesoblast ...

View the full article

[ImmInst]

Athersys (Nasdaq: ATHX) Targets GvHD and Related Market Opportunities with MultiStem®
BiotechStockTrader.com - 1 hour ago

By Justin Kuepper on Wednesday, June 1st, 2011 Athersys Inc. (Nasdaq: ATHX), a biopharmaceutical company focused on developing an innovative stem cell platform, similar to companies like Mesoblast ...

View the full article

[ImmInst]

BioTime CEO Dr. Michael West to Present at the Jefferies 2011 Global Healthcare Conference
Business Wire - 2 hours ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex: BTX) Chief Executive Officer, Michael D. West, Ph.D., is scheduled to speak during the Jefferies 2011 Global Healthcare Conference June ...

View the full article

[ImmInst]

BioTime Receives NIH Approval for Two GMP Human Embryonic Stem Cell Lines
Business Wire - 23 hours ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that two human ...

BioTime CEO Dr. Michael West to Present at the Jefferies 2011 Global Healthcare Conference - istockAnalyst.com

View the full article

[ImmInst]

BioTime receives NIH approval for two GMP human Embryonic Stem cell lines
pharmabiz.com - 17 minutes ago

BioTime, Inc. a biotechnology company that develops and markets products in the field of regenerative medicine, announced that two human Embryonic Stem (hES) cell lines, ESI-014 and ESI-017 ...

View the full article

[ImmInst]

Mesoblast Limited (ASX:MSB) To Present At Goldman Sachs (NYSE:GS) 32nd Annual Global Healthcare Conference
Asia Business News - 2 hours ago

Melbourne, June 6, 2011 (ABN Newswire) - Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that its Chief Executive, Silviu Itescu, will present at ...

MSB to Present at Goldman Sachs Global Healthcare Conference - irasia.com

View the full article

[ImmInst]

Mesoblast Limited (ASX:MSB) Revascor Increases Blood Supply to Damaged Heart Muscle
ABN Newswire - 1 hour ago

Melbourne, June 9, 2011 (ABN Newswire) - Results from Mesoblast Limited's (ASX:MSB) (PINK:MBLTY) cardiovascular clinical trials were featured at the Goldman Sachs 32nd Annual Global Healthcare ...

Phase 2 Clinical Trial Results Show That Revascor Increases Blood Supply to Damaged Heart Muscle - irasia.com

View the full article

[ImmInst]

BioTime Reports First Complete Sequencing of the Nuclear Genome of Five GMP-Compliant Human Embryonic Stem Cell Lines at Jefferies 2011 Global Healthcare Conference
Business Wire - 2 hours ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex:BTX) Chief Executive Officer, Michael D. West, Ph.D., will present today at the Jefferies 2011 Global Healthcare Conference in New York ...

Please check at http://www.istockanalyst.com for related articles, news, blogs and company research - istockAnalyst.com

View the full article

[ImmInst]

Mesoblast Limited (ASX:MSB) Key Product Franchises Featured at Nomura Asia Equity Forum
Asia Business News - 1 hour ago

Melbourne, June 14, 2011 (ABN Newswire) - Global regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), was featured today at the 8th Nomura Asia Equity Forum being held in ...

View the full article

[ImmInst]

Athersys (Nasdaq: ATHX) Reports Additional Phase I Heart Attack Study Data
BiotechStockTrader.com - 38 minutes ago

By Justin Kuepper on Tuesday, June 14th, 2011 Athersys Inc. (Nasdaq: ATHX), a biopharmaceutical company focused on developing an innovative stem cell platform, similar to companies like Mesoblast ...

View the full article

[ImmInst]

Healthcare Stocks: BTX, XOMA, SGEN
TomRollins.com - 2 hours ago

BioTime, Inc. (Public, AMEX:BTX). Last Market Price: 4.46, Change: -0.03, % Change: (-0.67%). Shares trade in the range of 4.34 – 4.62 dollars. It has a market capitalization of 217.64M dollars ...

View the full article

[ImmInst]

Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX
GuruFocus.com - 36 minutes ago

Last week's top five stocks that were bought by their CEOs were PCYC, HLX, FSC, CREG, and BTX. According to GuruFocus Insider Data, these are the largest CEO buys during the past week ...

View the full article

[ImmInst]

US Food and Drug Administration Clears Mesoblast Limited (ASX:MSB) Phase 2 Trial to Treat Degenerative Disc Disease
ABN Newswire - 1 hour ago

Melbourne, June 29, 2011 (ABN Newswire) - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and ...

View the full article

[ImmInst]

FDA Clears Mesoblast Ltd For Advanced Trials Of Back Pain Treatment-DJ
Reuters Key Development - 7 hours ago

View the full article

[ImmInst]

BioTime Announces Appointment of Chief Commercial Officer
MarketWatch - 2 hours ago

ALAMEDA, Calif., Jun 29, 2011 (BUSINESS WIRE) -- BioTime, Inc. /quotes/zigman/219441/quotes/nls/btx BTX +9.36% today announced the appointment of its Vice President of Business Development ...

View the full article

[ImmInst]

FDA Clears Mesoblast Limited Phase 2 Trial to Treat Degenerative Disc Disease
PharmaLive.com - 34 minutes ago

Melbourne, June 29, 2011 - (ABN Newswire) - Regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that it has received clearance from the United States Food and ...

View the full article